MediciNova, Inc.

NasdaqGM:MNOV Voorraadrapport

Marktkapitalisatie: US$102.0m

MediciNova Beheer

Beheer criteriumcontroles 2/4

De CEO MediciNova is Yuichi Iwaki, benoemd in Jan2000, heeft een ambtstermijn van 24.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.39M, bestaande uit 47.4% salaris en 52.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 2.23% van de aandelen van het bedrijf, ter waarde $ 2.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 8.3 jaar en 5.3 jaar.

Belangrijke informatie

Yuichi Iwaki

Algemeen directeur

US$1.4m

Totale compensatie

Percentage CEO-salaris47.4%
Dienstverband CEO24.8yrs
Eigendom CEO2.2%
Management gemiddelde ambtstermijn8.3yrs
Gemiddelde ambtstermijn bestuur5.3yrs

Recente managementupdates

Recent updates

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

Aug 28
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Apr 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Nov 27
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Jul 11
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

Mar 18
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

Oct 12
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

MediciNova to get US patent for MN-166 to treat brain cancer

Sep 15

MediciNova's MN-166 to be part of study to treat Long COVID

Aug 16

MediciNova begins study of parenteral formulation of MN-166

Jul 22

MediciNova announces extension of BARDA contract for Ibudilast development

Jun 30

We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

Mar 19
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely

MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

Nov 23
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business

MediciNova: The Pain Of A Positive Outlook

Aug 31

MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study

Jun 21

Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

May 15
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth

The MediciNova Riddle: Worth Unravelling

Apr 26

MediciNova inks $20M securities purchase agreement with 3D Investment Partners

Jan 12

MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis

Dec 29

MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans

Analyse CEO-vergoeding

Hoe is Yuichi Iwaki's beloning veranderd ten opzichte van MediciNova's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$10m

Jun 30 2024n/an/a

-US$8m

Mar 31 2024n/an/a

-US$8m

Dec 31 2023US$1mUS$657k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$12m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$620k

-US$14m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$3mUS$596k

-US$10m

Sep 30 2021n/an/a

-US$11m

Jun 30 2021n/an/a

-US$11m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$587k

-US$14m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$12m

Mar 31 2020n/an/a

-US$11m

Dec 31 2019US$4mUS$572k

-US$13m

Sep 30 2019n/an/a

-US$11m

Jun 30 2019n/an/a

-US$16m

Mar 31 2019n/an/a

-US$15m

Dec 31 2018US$3mUS$551k

-US$15m

Sep 30 2018n/an/a

-US$16m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$3mUS$534k

-US$11m

Compensatie versus markt: De totale vergoeding ($USD 1.39M ) Yuichi } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Yuichi is gestegen terwijl het bedrijf verliesgevend is.


CEO

Yuichi Iwaki (74 yo)

24.8yrs

Tenure

US$1,388,309

Compensatie

Dr. Yuichi Iwaki, M.D., Ph D., is a Co-Founder of MediciNova Inc. and has been its Chief Executive Officer and President since March 2006. Dr. Iwaki served as Acting Principal Financial Officer at MediciNo...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Yuichi Iwaki
Co-Founder24.8yrsUS$1.39m2.23%
$ 2.3m
Kazuko Matsuda
Chief Medical Officer & Director13.2yrsUS$1.01m0.66%
$ 671.8k
Jason Kruger
CFO & Principal Financial Officer2.4yrsgeen gegevensgeen gegevens
David Crean
Chief Business Officer3.5yrsgeen gegevensgeen gegevens
John O'Neil
Controllerno datageen gegevensgeen gegevens

8.3yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MNOV is doorgewinterd en ervaren (gemiddelde ambtstermijn van 8.3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Yuichi Iwaki
Co-Founder24.2yrsUS$1.39m2.23%
$ 2.3m
Kazuko Matsuda
Chief Medical Officer & Director5.3yrsUS$1.01m0.66%
$ 671.8k
Hideki Nagao
Independent Director7yrsUS$69.23k0%
$ 0
Carolyn Beaver
Independent Director4.1yrsUS$69.23k0%
$ 0
Nicole Lemerond
Independent Director1.3yrsUS$46.16k0%
$ 0

5.3yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MNOV wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.3 jaar).